Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Coordinated regulation of Ras-, Rac-, and Ca2+-dependent signaling pathways.

Grunicke HH.

Crit Rev Eukaryot Gene Expr. 2009;19(2):139-69. Review.

PMID:
19392649
2.

Regulation of calcium signalling by the small GTP-binding proteins Ras and Rac1.

Maly K, Hechenberger G, Strese K, Tinhofer I, Wede I, Doppler W, Grunicke HH.

Adv Enzyme Regul. 2007;47:169-83. Epub 2006 Dec 23. No abstract available.

PMID:
17374390
3.

Defining the human targets of phorbol ester and diacylglycerol.

Geiger M, Wrulich OA, Jenny M, Schwaiger W, Grunicke HH, Uberall F.

Curr Opin Mol Ther. 2003 Dec;5(6):631-41. Review.

PMID:
14755890
4.

Regulation of cell survival by atypical protein kinase C isozymes.

Grunicke HH, Spitaler M, Mwanjewe J, Schwaiger W, Jenny M, Ueberall F.

Adv Enzyme Regul. 2003;43:213-28. No abstract available.

PMID:
12791393
5.

Critical role of protein kinase C alpha and calcium in growth factor induced activation of the Na(+)/H(+) exchanger NHE1.

Maly K, Strese K, Kampfer S, Ueberall F, Baier G, Ghaffari-Tabrizi N, Grunicke HH, Leitges M.

FEBS Lett. 2002 Jun 19;521(1-3):205-10.

6.

Regulation of phospholipase D isoenzymes by transforming Ras and atypical protein kinase C-iota.

Mwanjewe J, Spitaler M, Ebner M, Windegger M, Geiger M, Kampfer S, Hofmann J, Uberall F, Grunicke HH.

Biochem J. 2001 Oct 1;359(Pt 1):211-7.

7.

Protein kinase C isoforms involved in the transcriptional activation of cyclin D1 by transforming Ha-Ras.

Kampfer S, Windegger M, Hochholdinger F, Schwaiger W, Pestell RG, Baier G, Grunicke HH, Uberall F.

J Biol Chem. 2001 Nov 16;276(46):42834-42. Epub 2001 Sep 10.

8.

Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities.

Rybczynska M, Spitaler M, Knebel NG, Boeck G, Grunicke H, Hofmann J.

Biochem Pharmacol. 2001 Sep 15;62(6):765-72.

PMID:
11551522
9.

Elements of signal transduction in drug discovery with special reference to inhibitors of protein kinase C.

Grunicke HH, Kampfer S, Spitaler M, Hochholdinger F, Baier G, Uberall F.

Ernst Schering Res Found Workshop. 2001;(34):81-99. Review. No abstract available.

PMID:
11394049
10.

MDR1 causes resistance to the antitumour drug miltefosine.

Rybczynska M, Liu R, Lu P, Sharom FJ, Steinfels E, Pietro AD, Spitaler M, Grunicke H, Hofmann J.

Br J Cancer. 2001 May 18;84(10):1405-11.

11.

Unique structural and functional properties of the ATP-binding domain of atypical protein kinase C-iota.

Spitaler M, Villunger A, Grunicke H, Uberall F.

J Biol Chem. 2000 Oct 27;275(43):33289-96.

12.

Implication of atypical protein kinase C isozymes lambda and zeta in Ras mediated reorganization of the actin cytoskeleton and cyclin D1-induction.

Hellbert K, Kampfer S, Maly K, Hochholdinger F, Mwanjewe J, Baier G, Uberall F, Grunicke HH.

Adv Enzyme Regul. 2000;40:49-62. Review. No abstract available.

PMID:
10828345
13.

The involvement of protein kinase C isoenzymes alpha, epsilon and zeta in the sensitivity to antitumor treatment and apoptosis induction.

Spitaler M, Wiesenhofer B, Biedermann V, Seppi T, Zimmermann J, Grunicke H, Hofmann J.

Anticancer Res. 1999 Sep-Oct;19(5B):3969-76.

PMID:
10628339
15.

Age-dependent deamidation of H1(0) histones in chromatin of mammalian tissues.

Lindner H, Sarg B, Grunicke H, Helliger W.

J Cancer Res Clin Oncol. 1999;125(3-4):182-6.

PMID:
10235472
16.

Evidence that atypical protein kinase C-lambda and atypical protein kinase C-zeta participate in Ras-mediated reorganization of the F-actin cytoskeleton.

Uberall F, Hellbert K, Kampfer S, Maly K, Villunger A, Spitaler M, Mwanjewe J, Baier-Bitterlich G, Baier G, Grunicke HH.

J Cell Biol. 1999 Feb 8;144(3):413-25.

17.
19.

PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1.

Spitaler M, Utz I, Hilbe W, Hofmann J, Grunicke HH.

Biochem Pharmacol. 1998 Oct 1;56(7):861-9.

PMID:
9774148
20.

Characterization of PKC isozyme specific functions in cellular signaling.

Kampfer S, Uberall F, Giselbrecht S, Hellbert K, Baier G, Grunicke HH.

Adv Enzyme Regul. 1998;38:35-48. No abstract available.

PMID:
9762345
22.

Transcriptional activation of c-fos by oncogenic Ha-Ras in mouse mammary epithelial cells requires the combined activities of PKC-lambda, epsilon and zeta.

Kampfer S, Hellbert K, Villunger A, Doppler W, Baier G, Grunicke HH, Uberall F.

EMBO J. 1998 Jul 15;17(14):4046-55.

23.

Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700.

Utz I, Spitaler M, Rybczynska M, Ludescher C, Hilbe W, Regenass U, Grunicke H, Hofmann J.

Int J Cancer. 1998 Jul 3;77(1):64-9.

24.

Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: synthesis and antiproliferative activity.

Easmon J, Heinisch G, Pürstinger G, Langer T, Osterreicher JK, Grunicke HH, Hofmann J.

J Med Chem. 1997 Dec 19;40(26):4420-5.

PMID:
9435912
25.

Conventional PKC-alpha, novel PKC-epsilon and PKC-theta, but not atypical PKC-lambda are MARCKS kinases in intact NIH 3T3 fibroblasts.

Uberall F, Giselbrecht S, Hellbert K, Fresser F, Bauer B, Gschwendt M, Grunicke HH, Baier G.

J Biol Chem. 1997 Feb 14;272(7):4072-8.

26.

Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).

Hofmann J, Utz I, Spitaler M, Hofer S, Rybczynska M, Beck WT, Herrmann DB, Grunicke H.

Br J Cancer. 1997;76(7):862-9.

27.

Differential Ca2+ signaling induced by activation of the epidermal growth factor and nerve growth factor receptors.

Tinhofer I, Maly K, Dietl P, Hochholdinger F, Mayr S, Obermeier A, Grunicke HH.

J Biol Chem. 1996 Nov 29;271(48):30505-9.

28.

Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.

Gekeler V, Boer R, Uberall F, Ise W, Schubert C, Utz I, Hofmann J, Sanders KH, Schächtele C, Klemm K, Grunicke H.

Br J Cancer. 1996 Sep;74(6):897-905.

29.

Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes.

Baier-Bitterlich G, Uberall F, Bauer B, Fresser F, Wachter H, Grunicke H, Utermann G, Altman A, Baier G.

Mol Cell Biol. 1996 Apr;16(4):1842-50.

31.

Cellular signalling as a target in cancer chemotherapy. Phospholipid analogues as inhibitors of mitogenic signal transduction.

Grunicke HH, Maly K, Uberall F, Schubert C, Kindler E, Stekar J, Brachwitz H.

Adv Enzyme Regul. 1996;36:385-407.

PMID:
8869757
32.

Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines.

Utz I, Gekeler V, Ise W, Beck J, Spitaler M, Grunicke H, Hofmann J.

Anticancer Res. 1996 Jan-Feb;16(1):289-96.

PMID:
8615623
33.

Activation of Ca2+ influx by transforming Ha-ras.

Maly K, Kindler E, Tinhofer I, Grunicke HH.

Cell Calcium. 1995 Aug;18(2):120-34.

PMID:
7585889
34.

Interference of new alkylphospholipid analogues with mitogenic signal transduction.

Maly K, Uberall F, Schubert C, Kindler E, Stekar J, Brachwitz H, Grunicke HH.

Anticancer Drug Des. 1995 Jul;10(5):411-25.

PMID:
7639930
35.

Signal transduction inhibitors.

Grunicke H.

Eur J Cancer. 1995;31A(5):833-4. No abstract available.

PMID:
7640072
36.

8th International AEK symposium of the Division of Experimental Cancer Research of the German Cancer Society. 29-31 March 1995, Heidelberg, Germany.

Rabes HM, Gabbert HE, Grunicke H, Lutz WK, Bornkamm G, Brandner G, Bosslet K, Rajewsky MF, Eisenbrand G, Schneider MR, et al.

J Cancer Res Clin Oncol. 1995;121(11):683-90. No abstract available.

PMID:
7593133
37.

Neopterin derivatives together with cyclic guanosine monophosphate induce c-fos gene expression.

Uberall F, Werner-Felmayer G, Schubert C, Grunicke HH, Wachter H, Fuchs D.

FEBS Lett. 1994 Sep 19;352(1):11-4.

38.

The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.

Utz I, Hofer S, Regenass U, Hilbe W, Thaler J, Grunicke H, Hofmann J.

Int J Cancer. 1994 Apr 1;57(1):104-10.

PMID:
7908658
39.

The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents.

Hofmann J, O'Connor PM, Jackman J, Schubert C, Ueberall F, Kohn KW, Grunicke H.

Biochem Biophys Res Commun. 1994 Mar 15;199(2):937-43.

PMID:
8135843
40.
42.

7th International Symposium of the Division of Experimental Cancer Research (AEK) of the German Cancer Society. 24-26 March, 1993, Heidelberg, Germany.

Grunicke H, Pyerin W, Eisenbrand G, Havemann K, Rabes HM, Molling K, Schwab M, Lutz WK, Wahrendorf J, Schirrmacher V, et al.

J Cancer Res Clin Oncol. 1994;120(3):179-85. No abstract available.

PMID:
8263016
43.

Role of protein kinases in antitumor drug resistance.

Grunicke H, Hofmann J, Utz I, Uberall F.

Ann Hematol. 1994;69 Suppl 1:S1-6. Review.

PMID:
8061107
44.

Role of protein kinase C in ras-mediated fos-expression.

Uberall F, Kampfer S, Schubert C, Doppler W, Grunicke HH.

Adv Enzyme Regul. 1994;34:257-68.

PMID:
7942278
45.

Role of GTPases and GTPase regulatory proteins in oncogenesis.

Grunicke HH, Maly K.

Crit Rev Oncog. 1993;4(4):389-402. Review.

PMID:
8353139
46.

Protein kinase C modulation.

Grunicke HH, Uberall F.

Semin Cancer Biol. 1992 Dec;3(6):351-60. Review.

PMID:
1286156
47.

Effects of inhibitors and ion substitutions on oscillations of cell membrane potential in cells expressing the RAS oncogene.

Lang F, Waldegger S, Woell E, Ritter M, Maly K, Grunicke H.

Pflugers Arch. 1992 Aug;421(5):416-24.

PMID:
1461714
48.

Tissue-specific pattern of nonhistone high mobility group proteins in various organs of the chicken.

Pedrini M, Grunicke H, Csordas A.

Electrophoresis. 1992 Jun;13(6):397-9.

PMID:
1505502
49.

Altered cell volume regulation in ras oncogene expressing NIH fibroblasts.

Lang F, Ritter M, Wöll E, Weiss H, Häussinger D, Hoflacher J, Maly K, Grunicke H.

Pflugers Arch. 1992 Apr;420(5-6):424-7.

PMID:
1614815
50.

Mechanism of intracellular calcium oscillations in fibroblasts expressing the ras oncogene.

Wöll E, Waldegger S, Lang F, Maly K, Grunicke H.

Pflugers Arch. 1992 Feb;420(2):208-12.

PMID:
1620579

Supplemental Content

Loading ...
Support Center